Navigating the world of cell and gene therapy development and commercialisation

By Annabel Kartal-Allen | Published: 27-Sep-2024
Cell & Gene Therapy

Manufacturing Chemist’s Annabel Kartal-Allen (AKA) spoke to Adam Goldstein (AG), Senior Director of R&D Collaborations at Thermo Fisher Scientific, about the current trends in CGT manufacturing and how to optimise and commercialise the process

You need to be a subscriber to read this article.
Click here to find out more.

Initially discussing the latest trends in the biopharma industry, Adam notes that process analytical technology (PAT) has seen significant evolution in recent years and become an important component in terms of accelerating development timelines. PAT solutions enable the simple scaling of manufacturing processes to facilitate the production of biologics and cell and gene therapies (CGTs).

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Thermo Fisher Scientific
See more

You may also like

Manufacturing

Thermo Fisher Scientific enhances biologics manufacturing sustainability with biobased solutions

Read more
The single use, plant-based film for bioprocessing containers can reduce the carbon footprint of biologics manufacturing by eliminating the need for plastic resin

Trending Articles

  1. Astraveus achieves end-to-end CAR-T production for the first time in history The Lakhesys Benchtop Cell Factory utilises advanced microfluidic technology to produce CAR-T cells in a rapid and cost-effective manner
  2. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  3. PCR-ELISA proves problematic in gene therapy measurement, determines NIST study PCR-ELISA was considered the least accurate and precise assay when quantifying the concentration of genetic and viral particles in an AAV, suggesting it may not be suitable for gene therapy measurement in its current form
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why potency assays are a crucial consideration for CGT manufacturers Potency assays can enhance the efficiency of cell and gene therapy development and commercialisation while also bringing down costs
  5. Why CGT manufacturers should automate the production process Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Thermo Fisher Scientific enhances biologics manufacturing sustainability with biobased solutions

The single use, plant-based film for bioprocessing containers can reduce the carbon footprint of biologics manufacturing by eliminating the need for plastic resin
Manufacturing

Multiply Labs and Thermo Fisher Scientific expand partnership to automate cell expansion and separation

Automating GMP-ready instruments using robotic technology helps reduce costs and accelerates timelines
Finance

Funding for commercialisation of Rexgenero cell therapy

TrakCel, a specialist software developer for cell and gene therapy supply chain tracking and orchestration, announced the consortium comprising itself, the Cell and Gene Therapy (CGT) Catapult, Rexgenero and Fisher Bioservices (part of Thermo Fisher Scientific) has secured funding of £1.4 million from Innovate UK
Research & Development

New pluripotent stem cell media eliminates need for daily feeding

Allows two full-day breaks without changes to set up or protocol
Manufacturing

Accellta grants feeder-free stem cell culture medium rights to Thermo Fisher

Stem cell company grants worldwide non-exclusive rights to Thermo Fisher to manufacture and distribute its proprietary cell culture medium and ancillary products and methods
Manufacturing

Astraveus achieves end-to-end CAR-T production for the first time in history

The Lakhesys Benchtop Cell Factory utilises advanced microfluidic technology to produce CAR-T cells in a rapid and cost-effective manner
Regulatory

PCR-ELISA proves problematic in gene therapy measurement, determines NIST study

PCR-ELISA was considered the least accurate and precise assay when quantifying the concentration of genetic and viral particles in an AAV, suggesting it may not be suitable for gene therapy measurement in its current form
Subscribe now